X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
neurosciences (681) 681
pharmacology & pharmacy (668) 668
animals (478) 478
dopamine d-2 receptor (419) 419
male (410) 410
psychiatry (395) 395
index medicus (381) 381
schizophrenia (379) 379
humans (365) 365
rats (336) 336
dopamine d (256) 256
dopamine d-2 receptors (251) 251
dopamine (228) 228
dopamine-d-2 receptors (209) 209
brain (181) 181
clinical neurology (180) 180
female (179) 179
binding (162) 162
receptor (160) 160
haloperidol (146) 146
pet (144) 144
positron-emission-tomography (144) 144
positron emission tomography (138) 138
biochemistry & molecular biology (134) 134
dopamine d 2 receptor (133) 133
clozapine (129) 129
receptors (129) 129
dopamine-d-2 receptor occupancy (127) 127
rats, sprague-dawley (127) 127
striatum (125) 125
receptors, dopamine d2 - metabolism (122) 122
adult (118) 118
in-vivo (118) 118
antipsychotic agents - pharmacology (117) 117
dose-response relationship, drug (115) 115
schizophrenia - drug therapy (111) 111
rat (110) 110
risperidone (110) 110
antipsychotics (102) 102
mice (102) 102
nucleus-accumbens (102) 102
rat-brain (101) 101
parkinsons-disease (100) 100
atypical antipsychotics (92) 92
antipsychotic agents - therapeutic use (90) 90
basal ganglia (87) 87
prefrontal cortex (86) 86
dopamine-d-2 (85) 85
double-blind (85) 85
brain - metabolism (83) 83
parkinson's disease (82) 82
antipsychotic agents - adverse effects (80) 80
aripiprazole (80) 80
dopamine d-1 receptor (79) 79
behavioral sciences (78) 78
dopamine - metabolism (78) 78
olanzapine (77) 77
chemistry, medicinal (74) 74
dopamine antagonists - pharmacology (74) 74
radiology, nuclear medicine & medical imaging (73) 73
antipsychotic-drugs (71) 71
pharmacology (70) 70
drugs (69) 69
activation (68) 68
corpus striatum - metabolism (68) 68
motor activity - drug effects (68) 68
antipsychotic drugs (67) 67
neurons (67) 67
antipsychotic (66) 66
dopamine agonists - pharmacology (64) 64
occupancy (64) 64
rats, wistar (64) 64
middle aged (63) 63
schizophrenic-patients (63) 63
antipsychotic agents - administration & dosage (62) 62
dopamine d-2 (61) 61
dopamine-d-2 receptor (61) 61
neuroleptics (61) 61
brain - drug effects (60) 60
messenger-rna (60) 60
article (59) 59
d2 receptors (59) 59
expression (58) 58
quinpirole (58) 58
behavior, animal - drug effects (57) 57
dopamine d2 receptor (57) 57
adenosine a receptors (54) 54
serotonin (53) 53
antagonist (52) 52
central-nervous-system (52) 52
release (52) 52
time factors (52) 52
corpus striatum - drug effects (51) 51
dopamine d2 receptors (51) 51
human brain (51) 51
apomorphine (50) 50
c-11 raclopride (50) 50
raclopride (50) 50
receptors, dopamine - drug effects (50) 50
stimulation (50) 50
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1519) 1519
German (7) 7
French (5) 5
Japanese (5) 5
Spanish (2) 2
Chinese (1) 1
Danish (1) 1
Dutch (1) 1
Italian (1) 1
Polish (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, ISSN 0027-8424, 07/2015, Volume 112, Issue 27, pp. E3609 - E3618
Adenosine A(2A) receptor (A(2A)R)-dopamine D-2 receptor (D2R) heteromers are key modulators of striatal neuronal function. It has been suggested that the... 
GPCR heteromers | HETEROMERS | dopamine D-2 receptor | caffeine | DETERMINANTS | AFFINITY | MULTIDISCIPLINARY SCIENCES | COMPLEXES | adenosine A(2A) receptor
Journal Article
JOURNAL OF MEDICINAL CHEMISTRY, ISSN 0022-2623, 05/2014, Volume 57, Issue 9, pp. 3623 - 3650
The adenosine A(2A) receptor is a G-protein-coupled receptor (GPCR) that has been extensively studied during the past few decades because it offers numerous... 
MEDICINAL CHEMISTRY | CHEMISTRY, MEDICINAL | POSITRON-EMISSION-TOMOGRAPHY | PHARMACOLOGICAL CHARACTERIZATION | LEAD OPTIMIZATION | STRUCTURE-AFFINITY RELATIONSHIPS | SELECTIVE AGONISTS | ALLOSTERIC MODULATION | BINDING CHARACTERISTICS | DOPAMINE-D-2 RECEPTORS | PARKINSONS-DISEASE
Journal Article
JOURNAL OF MEDICINAL CHEMISTRY, ISSN 0022-2623, 09/2009, Volume 52, Issue 18, pp. 5590 - 5602
Adenosine A(2A) (A(2A)R) and dopamine D-2 (D2R) receptors mediate the antagonism between adenosinergic and dopaminergic transmission in striatopallidal... 
CHEMISTRY, MEDICINAL | FLUORESCENCE | MEMBRANE | QUANTITATIVE ASSESSMENT | HIGH-AFFINITY | PROTEIN-COUPLED RECEPTORS | HETERODIMERIZATION | DOPAMINE-D-2 RECEPTORS | OLIGOMERIZATION | QUATERNARY STRUCTURE PREDICTIONS | HOMODIMERIZATION
Journal Article
Philosophical Transactions of the Royal Society B: Biological Sciences, ISSN 0962-8436, 10/2008, Volume 363, Issue 1507, pp. 3125 - 3135
Journal Article
JOURNAL OF MEDICINAL CHEMISTRY, ISSN 0022-2623, 07/2019, Volume 62, Issue 13, pp. 6287 - 6314
Because of the large degree of homology among dopamine D-2-like receptors, discovering ligands capable of discriminating between the D-2, D-3, and D-4 receptor... 
CHEMISTRY, MEDICINAL | ANALOGS | DETERMINANTS | CRYSTAL-STRUCTURE | BIVALENT LIGANDS | PHARMACOLOGY | SEEKING BEHAVIOR | HIGH-AFFINITY | DOPAMINE-D-2 | ANTAGONISTS | ADDICTION
Journal Article
MOLECULAR PHARMACOLOGY, ISSN 0026-895X, 09/2019, Volume 96, Issue 3, pp. 308 - 319
The dopamine D2 receptor (D2R) mediates ligand-biased signaling with potential therapeutic implications. However, internalization, choice of endocytic routes,... 
PATHWAYS | BETA-ARRESTIN2 | DOPAMINE-D-2 RECEPTOR | SEROTONIN 5-HT1A | INTERNALIZATION | ANTIPSYCHOTICS | FUNCTIONAL SELECTIVITY | PHARMACOLOGY & PHARMACY | G-PROTEIN | DISCOVERY | ARIPIPRAZOLE
Journal Article
NEUROSCIENCE LETTERS, ISSN 0304-3940, 08/2019, Volume 707, p. 134292
The mechanisms underlying the beneficial effects of clozapine (CLZ) in the treatment of schizophrenia still remains far from clear. In the present work we... 
ATYPICAL ANTIPSYCHOTIC-DRUGS | Autoradiography | Ketamine | Dopamine D-2 receptors | SCHIZOPHRENIA | MECHANISMS | Clozapine | MODEL | In situ hybridization | EXPRESSION | NEUROSCIENCES
Journal Article
TRENDS IN NEUROSCIENCES, ISSN 0166-2236, 11/2006, Volume 29, Issue 11, pp. 647 - 654
The adenosine A(2A) receptor has emerged as an attractive non-dopaminergic target in the pursuit of improved therapy for Parkinson's disease (PD), based in... 
DOPA-INDUCED DYSKINESIA | TURNING BEHAVIOR | GLOBUS-PALLIDUS | BIOLUMINESCENCE ENERGY-TRANSFER | CENTRAL-NERVOUS-SYSTEM | 6-HYDROXYDOPAMINE-LESIONED RATS | BINDING CHARACTERISTICS | DOPAMINE-D-2 RECEPTORS | NEUROSCIENCES | C-FOS EXPRESSION | SYNERGISTIC INTERACTION | Neurosciences | Adenosine | Parkinson's disease | Research | Drug therapy
Journal Article
Philosophical Transactions of the Royal Society B: Biological Sciences, ISSN 0962-8436, 10/2008, Volume 363, Issue 1507, pp. 3191 - 3200
Journal Article
MOLECULAR NEUROBIOLOGY, ISSN 0893-7648, 06/2018, Volume 55, Issue 6, pp. 4952 - 4958
Dopamine D-2 receptor (D2R) activation triggers both G protein- and beta-arrestin-dependent signaling. Biased D2R ligands activating beta-arrestin pathway have... 
BRET | RECRUITMENT | ACTIVATION | Oligomerization | ANTAGONIST | Functional selectivity, biased ligand, dopamine D-2 receptor | beta-arrestin | SCHIZOPHRENIA | NEUROSCIENCES | HETEROMERIZATION | BETA-ARRESTIN2 | D2 RECEPTOR | AdenosineA2A receptor | PHARMACOLOGY | FUNCTIONAL SELECTIVITY | MODULATION
Journal Article
Journal of Clinical Psychopharmacology, ISSN 0271-0749, 09/2016, Volume 36, Issue 6, pp. 733 - 735
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 06/2017, Volume 60, Issue 11, pp. 4693 - 4713
By means of a formal structural hybridization of the antipsychotic drug aripiprazole and the heterocyclic catecholamine surrogates present in the... 
BETA-ADRENOCEPTOR AGONIST | QT PROLONGATION | DOPAMINE-D-2 RECEPTOR | CHEMISTRY, MEDICINAL | DOPA-INDUCED DYSKINESIA | RECEPTOR PARTIAL AGONISTS | FUNCTIONAL SELECTIVITY | G-PROTEIN | BINDING | DISCOVERY | PARKINSONS-DISEASE
Journal Article
Schizophrenia Research, ISSN 0920-9964, 2017, Volume 194, pp. 32 - 38
Abstract Objective Cannabis use disorders (CUDs) are highly comorbid in patients with schizophrenia and associated with poor outcome. Clozapine has been put... 
Psychiatry | Schizophrenia | Cannabis | Clozapine | Risperidone | Craving | Imaging | SUBSTANCE-ABUSE | ACTIVATION | PSYCHIATRY | NEURAL BASIS | RISK | OCCUPANCY | ATYPICAL ANTIPSYCHOTICS | ADDICTION | OUTCOMES | DOPAMINE-D-2 RECEPTORS | BRAIN
Journal Article
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, ISSN 0271-0749, 07/2019, Volume 39, Issue 4, pp. 329 - 335
Purpose/Background Patients with schizophrenia as well as their psychiatrists are hesitant to reduce the antipsychotic dose in fear of relapse. To overcome... 
dopamine D-2 receptor | PSYCHIATRY | SENSITIVITY | RISPERIDONE | schizophrenia | DOPAMINE-D-2 RECEPTOR OCCUPANCY | PLASMA-LEVELS | maintenance treatment | DRUGS | PHARMACOLOGY & PHARMACY | antipsychotic | OLANZAPINE | SCALE | DOSAGE | PET
Journal Article
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, ISSN 0223-5234, 04/2019, Volume 168, pp. 474 - 490
We recently described a structurally novel series of negative allosteric modulators (NAMs) of the dopamine D-2 receptor (D2R) based on thieno[2,3-d]pyrimidine... 
DESIGN | CHEMISTRY, MEDICINAL | Dopamine D-2 receptor | ANTAGONIST | D-3 | IDENTIFICATION | DISCOVERY | Thieno[2,3-d]pyrimidines | SB269652 | MODELS | Negative allosteric modulators | PHARMACOLOGY | Agonists | LIGAND | INHIBITORS | NAMs
Journal Article